文献速递神经肿瘤小儿神经外科与脑积水

非典型畸胎样横纹肌样瘤:分子机制与新型治疗转化

Atypical teratoid rhabdoid tumor: molecular insights and translation to novel therapeutics.
PubMed 文献 · J Neurooncol · 2020-10-06

非典型畸胎样横纹肌样瘤(ATRT)是罕见的儿童致死性脑肿瘤,遗传背景简单但表观遗传复杂。综述回顾关键分子发病机制、已定义亚型及临床试验,指出SMARCB1缺失是核心事件,导致表观遗传失调和谱系特异性增强子丢失,当前研究正制定针对亚型的靶向治疗。

要点

  • SMARCB1缺失是ATRT发病关键遗传事件。
  • SMARCB1缺失导致广泛表观遗传失调和增强子丢失。
  • 研究正定义针对分子紊乱的亚型特异性治疗。

核心结论

  • SMARCB1缺失是ATRT核心致病事件,通过表观遗传失调驱动肿瘤发生。
  • 亚型特异性治疗是当前转化研究方向。

研究设计与样本

  • 综述回顾ATRT关键研究,聚焦分子发病机制及其与新型治疗的相关性。

主要发现

  • ATRT为儿童罕见致死性脑肿瘤,遗传背景简单但表观遗传复杂。
  • 近期分子研究定义了肿瘤发生关键生物学事件及ATRT分子亚型。
  • SMARCB1缺失导致广泛表观遗传失调和谱系特异性增强子丢失。

临床怎么用

  • 基于分子亚型开展靶向治疗临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Atypical teratoid rhabdoid tumor (ATRT) is a rare, often lethal brain tumor of childhood characterized by a complex epigenetic landscape amongst a simple genetic background. Recent molecular studies have defined key biologic events that contribute to tumorigenesis and molecular subtypes of ATRT. METHODS: Seminal studies on ATRT are reviewed with an emphasis on molecular pathogenesis and its relevance to novel therapeutics. RESULTS: In this review, we summarize the key clinicopathologic and molecular features of ATRT, completed and ongoing clinical trials and outline the translational potential of novel insights into the molecular pathogenesis of this tumor. CONCLUSIONS: SMARCB1 loss is the key genetic event in ATRT pathogenesis that leads to widespread epigenetic dysregulation and loss of lineage-specific enhancers. Current work is defining subtype-specific treatments that target underlying molecular derangements that drive tumorigenesis.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Nesvick CL, Lafay-Cousin L, Raghunathan A, et al. Atypical teratoid rhabdoid tumor: molecular insights and translation to novel therapeutics. J Neurooncol. 2020. PMID: 33021733. doi:10.1007/s11060-020-03639-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。